IBM’s Rally: A Quantum Policy Windfall and Software Strength, Shadowed by an AI Literacy Gap

IBM shares have clawed back nearly 10% over the past seven trading days, closing Friday at €237.80 and reclaiming the 200-day moving average. That milestone – the line currently sits at €235.90 – marks a critical technical recovery from the 52-week low of €181.32 touched in mid-May. Yet the stock still sits roughly 19% below its early-June zenith, and the forces driving this rebound are as much about geopolitics as they are about profits.

The most powerful catalyst came from the Oval Office. On June 22, President Trump signed two executive orders setting hard deadlines for quantum-computing development and mandating a rapid federal migration to quantum‑safe encryption. Flanked by IBM chief Arvind Krishna and Alphabet president Ruth Porat, Trump announced that the Commerce Department would channel $2 billion into nine quantum companies. IBM alone receives $1 billion for a new joint venture, cementing its role as the dominant player in the nascent ecosystem. The government backing is a clear political tailwind, but it also exposes IBM to the whims of an administration whose priorities can shift abruptly.

Investors have enthusiastically bought the quantum narrative, but the company’s internal research suggests a fundamental disconnect. The IBM Institute for Business Value recently surveyed executives and found that a staggering 91% of leaders do not fully understand their own AI dependencies. That knowledge gap is causing customers to delay large‑scale deployments, casting a cloud over the Watsonx platform that the company has bet heavily on. For all the excitement in the White House, the ground‑level reality is that many corporate clients are hesitant to commit to complex AI projects when they lack a clear grasp of the technology.

The tension between political hype and operational reality will come to a head on July 22, when IBM reports second‑quarter earnings. Analysts are looking for revenue of roughly $17.8 billion, with per‑share profit estimates hovering between $2.98 and $3.00. The market will scrutinize whether IBM can finally convert its much‑vaunted AI order backlog into booked revenue. If the numbers fall short, the shares risk giving back this month’s gains.

Should investors sell immediately? Or is it worth buying IBM?

Beyond quantum and AI, the bedrock of IBM’s bull case remains its software segment. The division accounts for about 45% of revenue and delivers roughly two‑thirds of total profit, driven by Red Hat and a growing roster of AI offerings. A wave of analyst upgrades has reinforced that narrative. JPMorgan lifted its price target from $270 to $291 and raised the stock to Overweight, with analyst Brian Essex citing software as the central profit engine. Morgan Stanley set a target of $267, while Citigroup sees fair value as high as $375.

The consulting arm, however, remains a persistent drag. After the first‑quarter report, in which management merely reaffirmed the full‑year outlook rather than boosting it, shares slid 6%. Investors are wary of a repeat performance, and the earnings call on July 22 will need to show that the advisory business is stabilizing.

Meanwhile, IBM is pouring more than $10 billion into quantum computing through 2031, including the Anderon project, billed as the world’s first dedicated quantum‑wafer fab. That investment may take years to yield commercial returns, but the immediate political commitment has already lifted sentiment. In the shorter term, the 200‑day moving average now serves as the key support level. As long as that line holds, the recovery story stays alive – even if the path to a full breakout is paved with questions about AI adoption and consulting margins.